Opinion|Videos|November 20, 2024
Looking Ahead and Key Takeaways
Elizabeth O’Donnell, MD, comments on the most significant advancements for frontline therapy in transplant-ineligible patients with newly diagnosed multiple myeloma. She also provides key takeaways from the latest clinical trial data, discussing how she anticipates these findings will impact her day-to-day clinical practice.
Advertisement
Episodes in this series
- Please comment on the most significant advancements on the horizon for frontline therapy in both transplant-ineligible patients with newly diagnosed multiple myeloma.
- Provide your key takeaways from the latest clinical trial data and how you anticipate these findings will impact your day-to-day clinical practice.
Advertisement
Related to this article
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
A 3-year, $225K award will focus on improving quality of life for patients living with long-term effects of cancer treatment.
China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.
An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Faculty reviewed data-driven advances in treatment intensification, sequencing, and emerging biomarkers across the prostate cancer and RCC continuums.
Sacituzumab govitecan produced an ORR of 35% in heavily pretreated platinum-resistant ovarian cancer in a phase 2 study.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
NMPA Accepts Toripalimab Plus Chemotherapy Application for Expanded Stage II-III NSCLC Use
4
Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer
5